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Abstract
Background: The apolipoprotein E gene (APOE) coding polymorphism modifies the risks of Alzheimer’s disease, type 2
diabetes, and coronary heart disease. Aside from the coding variants, single nucleotide polymorphism (SNP) of the APOE
promoter has also been shown to modify the risk of Alzheimer’s disease.
Methodology/Principal Findings: In this study we investigate the genotype-function relationship of APOE promoter
polymorphism at molecular level and at physiological level: i.e., in transcription control of the gene and in the risk of type 2
diabetes. In molecular studies, the effect of the APOE 2491A/T (rs449647) polymorphism on gene transcription was
accessed by dual-luciferase reporter gene assays. The 2491 A to T substitution decreased the activity (p,0.05) of the cloned
APOE promoter (21017 to +406). Using the 2501 to 2481 nucleotide sequence of the APOE promoter as a ‘bait’ to screen
the human brain cDNA library by yeast one-hybrid system yielded ATF4, an endoplasmic reticulum stress response gene, as
one of the interacting factors. Electrophoretic-mobility-shift assays (EMSA) and chromatin immuno-precipitation (ChIP)
analyses further substantiated the physical interaction between ATF4 and the APOE promoter. Over-expression of ATF4
stimulated APOE expression whereas siRNA against ATF4 suppressed the expression of the gene. However, interaction
between APOE promoter and ATF4 was not 2491A/T-specific. At physiological level, the genotype-function relationship of
APOE promoter polymorphism was studied in type 2 diabetes. In 630 cases and 595 controls, three APOE promoter SNPs
2491A/T, 2219G/T (rs405509), and +113G/C (rs440446) were genotyped and tested for association with type 2 diabetes in
Hong Kong Chinese. No SNP or haplotype association with type 2 diabetes was detected.
Conclusions/Significance: At molecular level, polymorphism 2491A/T and ATF4 elicit independent control of APOE gene
expression. At physiological level, no genotype-risk association was detected between the studied APOE promoter SNPs and
type 2 diabetes in Hong Kong Chinese.
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Introduction
Type 2 diabetes is a multi-factorial and polygenic disease which
makes up 90% of all cases of diabetes. Dyslipidemia is one of the
risk factors for type 2 diabetes as well as for diabetic complications,
such as coronary heart disease, diabetic nephropathy and
retinopathy [1,2].
Apolipoprotein E (apoE) is a 34 kD protein which plays a
central role in lipid metabolism. Two coding polymorphisms of the
gene resulting in three protein variants apoE2, apoE3 and apoE4
incur isoform-dependent risk associations with Alzheimer’s
disease, atherosclerosis and coronary heart disease [3]. ApoE is
also an important molecule in the development and progression of
diabetes. A recent meta-analysis of genome-wide linkage studies of
quantitative lipid traits in families ascertained for type 2 diabetes
with diverse ethnic backgrounds identified one of the linkage
region for lipid traits on chromosome 19q13.13-13.43 which
included the APOE gene locus (19q13.2) [4]. Another meta-
analysis on data of 5423 cases and 8197 controls extracted from 30
studies provided evidence that the APOE2 allele carriers have
elevated risk for type 2 diabetes [5]. Aside from the isoform-
dependent effects, plasma apoE has been associated with the risk
of cardiovascular diseases in a dose-dependent manner [6]. An
increment of plasma apoE in type 2 diabetic patients as compared
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transcriptional activity of APOE may affect plasma concentration
of the protein. An increasing body of evidence has associated
APOE promoter polymorphisms with human diseases. For
example, the APOE promoter 2491A genotype has been
associated with a higher plasma level of apoE and increased risk
for Alzheimer’s disease as compared to its 2491T counterpart
[8,9]. In spite of the association between APOE promoter
polymorphisms and disease risks, the underlying mechanisms
responsible for controlling APOE gene expression remain elusive.
In this study, we aimed at elucidating the genotype-function
relationship of APOE promoter polymorphism at molecular and
physiological levels. At molecular level, we further investigated the
transcriptional control mechanism at the 2491A/T-spanning
region of APOE. At physiological level, we examined the
association of APOE promoter polymorphisms 2491A/T
(rs449647), 2219G/T (rs405509) and +113G/C (rs440446) with
the risk of type 2 diabetes. These three SNPs were chosen for
analysis based on their previously reported association with
Alzheimer’s disease and coronary heart disease [10,11]. Investi-
gation of association between these SNPs and type 2 diabetes has
not been reported. Our molecular studies demonstrate for the first
time that ATF4, a key transcription factor mediating ER
(endoplasmic reticulum) stress response and regulates lipid and
glucose homeostasis in mammals [12], is interactive with the APOE
promoter and controls the expression of the gene independent of
the control elicited by the 2491A/T polymorphism. At physio-
logical level, no association was detected between the three APOE
promoter SNPs and the risk of type 2 diabetes in Hong Kong
Chinese.
Results
2491A/T polymorphism regulates APOE promoter
activity
The effects of 2491A/T polymorphism on the activities of the
APOE gene were analyzed by dual-luciferase reporter assay.
Figure 1A shows that 2491A to T single nucleotide substitution
significantly changed APOE promoter activity in WRL-68 (human
hepatic embryonic) and U-87 (human astrocytic) cell lines
(decrease of 14% and 36%, respectively, p,0.05). These results
support that the APOE promoter 2491 polymorphism is
functionally active and elicits similar regulatory effects on APOE
transcription in human cell lines of liver and brain origins. Further
analyses by EMSA revealed the interaction of nuclear proteins
with APOE promoter 2491A/T-spanning sequence (2521 to
2461) (Figure 1B). Subsequent studies were carried out to identify
the potential interacting transcription factors with APOE promoter
2491A/T-spanning region.
ATF4 is a candidate transcription factor binding to APOE
promoter 2491A/T- spanning sequence
Yeast one-hybrid screening of a human brain cDNA library
identified ATF4 being one of the candidate transcription factors
interactive with the APOE 2491-spanning sequence. ATF4
belongs to ATF/CREB transcription factor family that mainly
involves in the PERK endoplasmic reticulum (ER) stress
response. It is well known that the dysfunction of ER stress
responses can result in various diseases including diabetes,
Alzheimer’s disease and inflammation [13]. Further bioinfor-
matic analysis using the TRANSFAC 6.0 database identified a
sequence homologous to the ATF/CRE core binding site
(TGACCTTA, 2486 to 2479) adjacent to the studied APOE
promoter 2491A/T-spanning region. Taken together, ATF4 was
selected as a candidate transcription factor for further investiga-
tion of its interaction with APOE promoter and the regulation of
APOE gene transcription.
ATF4 interacts with APOE promoter 2491A/T-spanning
sequence in vitro and in vivo
To further verify the direct interaction between APOE promoter
and ATF4, EMSA was performed using purified recombinant His-
tagged ATF4 and 2491A or 2491T probes (2521 to 2461).
Clear shift of bands were detected for both 2491A and T probes
(Figure 2A). Addition of excessive unlabeled probes completely
competed with the labeled probe for ATF4 binding, indicating this
binding is specific. Further super-shift assay with ATF4-specific
antibody lead to a super-shift band for both 2491A and 2491T
probes as shown in Figure 2B. ChIP assays were performed to
further confirm the binding of ATF4 and APOE promoter
2491A/T-spanning locus in vivo. Results in Figure 2C showed
that APOE promoter 2617 to 2344 region encompassing the
2491A/T-spanning site could be amplified only from the anti-
ATF4 antibody immuno-precipitated complex, while PCR
product was merely detectable in the IgG control both in 293
cells (2491AA genotype) and WRL-68 cells (2491TT genotype).
Taken together, these results further substantiated the physical
interaction between ATF4 and the APOE promoter at the
2491A/T-spanning region both in vitro and in vivo.
ATF4 regulates APOE transcription and expression
To elucidate the biological effects of ATF4 interaction with
APOE promoter 2491A/T-spanning region, the APOE promoter
firefly reporter constructs (with 2491A or 2491T allelic form),
pcDNA3.1-ATF4 mammalian expression vector (or pcDNA3.1
empty vector) and the internal control Renilla luciferase reporter
vector were co-transfected into mammalian cells. Dual-luciferase
reporter assays showed that ATF4 over-expression significantly
suppressed the APOE promoter (with 2491A) activity in U-87 cells
by about 50% (Figure 3A). Site-directed mutagenesis was
performed to generate an APOE promoter deletion mutant
D(2487 to 2469) reporter construct spanning the putative
ATF4 binding site. Abolishing this putative ATF4 binding site
resulted in 20% increase of APOE promoter activity as compared
to the full-length APOE promoter (2491A allelic form) (Figure 3B).
Furthermore, the suppressive effect of ATF4 on APOE promoter
activity was dose-dependent with statistical significant effects
observed at higher dosages (Figure 3C). ATF4 over-expression
significantly down-regulated the activities of cloned APOE
promoters both in 2491A and 2491T allelic forms in U-87 and
WRL-68 cells (Figure 3D) although no apparent allelic-difference
was observed. These results strongly support that ATF4 modulates
the transcriptional activity of APOE promoter.
We next examined the effects of ATF4 on the expression of
endogenous APOE. Blockage of the endogenous ATF4 expression
by siRNA in WRL68 human hepatic cells caused a 42% reduction
of endogenous APOE expression (Figure 4A). On the other hand,
over-expression of ATF4 enhanced APOE mRNA expression
(Figure 4B). These results further substantiated the functional role
of ATF4 in regulating APOE gene expression.
No association was detected between APOE promoter
polymorphism and the risk of type 2 diabetes
To investigate the genotype-function relationship of APOE
promoter polymorphism at physiological level, we tested the
association between APOE promoter SNPs and the risk of type 2
diabetes in Hong Kong Chinese. In our case-control study, the
APOE SNPs in Transcription Control and Diabetes
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type 2 diabetic patients (40.0768.39 years) but such difference is
not statistically significant after adjustment of multiple testing.
There is a female preponderance in the type 2 diabetes cohort
(55.1% in controls and 61% in type 2 diabetes, p=0.039). Type
2 diabetic patients had significantly higher BMI, WHR, blood
pressure, more adverse lipid profiles (high total cholesterol, high
LDL-C, low HDL-c and high TG), and higher plasma glucose
levels than non-diabetic control subjects (p,0.001) (Table S1).
All three APOE proximal promoter polymorphisms were
successfully genotyped with high call rates: 95.9% for 2491A/T
(rs449647), 99.8% for 2219G/T (rs405509) and 98.8% for
+113G/C (rs440446). All genotype distributions were in Hardy-
Weinberg equilibrium (HWE) in both type 2 diabetes and non-
diabetic control groups. APOE promoter 2491A/T, 2219G/T
and +113G/C genotype distributions and allele frequencies were
similar between the control and type 2 diabetes groups (Table 1).
Analysis with gender stratification did not reveal an association
between these SNPs and type 2 diabetes either. Linkage
disequilibrium (LD) analysis indicated that 2219G/T and
+113G/C polymorphisms form an LD block which is not linked
to the APOE 2491A/T polymorphism (Table S2). No association
was detected between haplotypes (formed between 2491A/T and
the 2219G/T-tagged LD block) and type 2 diabetes.
Figure 1. APOE promoter 2491A/T polymorphism is a functional variant. (A) 2491A to T single nucleotide substitution significantly
decreases the transcriptional activity of the APOE promoter. APOE promoter firefly luciferase reporter constructs (21017 to +406) containing A or T at
2491 site are designated 2491A or 2491T, respectively. Data are presented as APOE promoter (2491T) activity relative to that of its 2491A
counterpart (value set at 100%). Data are obtained from three to five independent experiments in triplicate set up. * p,0.05 by Student’s t-test. (B)
Interaction between nuclear factors and APOE promoter 2491A/T-spanning sequence. EMSA assays were performed in 20 ml reaction system
containing 3 nM of DIG-labeled 2491A or 2491T probe (2521 to 2461)65 mg of cell nuclear extracts. The absence (2) or the presence (+)o f
192 nM of unlabeled corresponding 2491A or 2491T probes served as the control or competition conditions for specific binding between the DIG-
labeled probe and nuclear proteins. Shift-bands are indicated by arrowheads. Non-specific shift-bands are indicated by ‘‘#’’. WRL68: human hepatic
embryonic cell line; U87: human astrocytic cell line; 293: human kidney epithelial cell line.
doi:10.1371/journal.pone.0024669.g001
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The results from the current and previous studies indicated that
the polymorphism of APOE promoter at the 2491 site is
functionally significant in modifying APOE gene transcription as
well as in the development of diseases [6,8]. However, the
transcriptional control mechanism of APOE at this locus has not
been well characterized. In this study, we presented evidence that
transcription factor ATF4 functionally regulates and physically
interacts with the APOE promoter. Such regulation is independent
of the 2491A/T polymorphism.
ATF4 is widely expressed in different organs including liver,
kidney, brain, spleen, heart, thymus, lung, blood cells and
fibroblasts [14]. It belongs to the ATF/CREB bZIP transcription
factor family and is a key transcription factor controlled under the
PERK signaling pathway which is up-regulated by ER stress – a
process referring to the excessive cellular protein load relative to
the reserve of ER chaperones required for correct folding of newly
synthesized membrane or secretary proteins [15]. ATF4 transla-
tion is induced upon ER stress followed by its migration to nucleus
to induce antioxidant genes and genes of the ER protein
maturation machinery [16].
ER stress and APOE have been independently associated with
neurodegenerative diseases and atherosclerosis [6,8,9,13]. Also ER
stress is related to the increased ATF4 expression as well as b-cell
apoptosis and the subsequent development of diabetes [17,18].
Given the important role of ATF4 in ER stress responses, the
control of APOE expression by ATF4 demonstrated in this study
provides a plausible link between ER stress and APOE-mediated
cellular function in disease processes.
Previous studies have reported the difference of APOE promoter
transcription activities elicited by the 2491A/T polymorphism in
human hepatocellular carcinoma HepG2 cells [19]. We have
obtained similar results in other cell types representing the major
apoE production tissues including WRL-68 human embryonic
hepatocytes and U-87 human astrocytes. APOE promoter in the
2491A allelic form was associated with higher transcriptional
activity as compared to its 2491T counterpart in both cell lines.
The magnitude of change was greater in astrocytes than that of the
liver cells. This may be explained by tissue-specific transcription
activities. These observations support that APOE promoter
2491A/T polymorphism is functionally active in regulating APOE
promoter in different tissues and justified further characterization
of the transcriptional control mechanism within this region.
Figure 2. ATF4 physically interacts with APOE promoter 2491-spanning region. (A) EMSA analyses were performed in 20 ml reaction system
containing 3 nM of DIG-labeled 2491A or 2491T probe (2521 to 2461)61.2 mM of the purified His-tagged ATF4 protein, the shift-bands are
indicated by solid arrowhead. (B) Super-shift assays are performed by the addition of ATF4 antibody into reaction mixture containing 2491A or
2491T probes and 0.7 mM purified ATF4 protein. The super-shift bands are indicated by unfilled arrowhead. (C) Chromatin Immunoprecipitation
(ChIP) assays confirmed the in vivo interaction of APOE promoter 2491-spanning sequence and ATF4 in 293 (2491AA genotype) and WRL68 (2491TT
genotype) cells.
doi:10.1371/journal.pone.0024669.g002
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(hepatoma) and NB (neuroblastoma) cells can bind to the
2491-spanning region of the APOE promoter [20,21] . However,
there has been no further resolution of the interacting proteins
with the APOE 2491-spanning sequence. In this study, yeast one-
hybrid screening and EMSA analyses identified and verified the
physical interaction between APOE promoter 2491–spanning
sequence and the transcription factor ATF4. Using the purified
recombinant ATF4 protein and the 2491A/T allelic oligonu-
cleotide probes, we found ATF4 interactive with these probes in
vitro. The results of ChIP assays further supported such physical
interaction in vivo.
The dual-luciferase assays reported the functional effects of
ATF4 on APOE promoter. ATF4 can suppress the activity of
APOE promoter in WRL-68 and U-87 cells. This suppressive effect
is common to both 2491A and T allelic forms. Consistently, the
suppressive effect of ATF4 did not significantly differ in magnitude
for the two 2491 allelic forms of the promoter in both cell lines
examined.
It is curious that the cloned APOE promoter and endogenous
APOE expression showed opposite responses to ATF4 over-
expression. It is well known that ATF4 can partner with different
transcription factors to act as a transcription repressor or activator
[22]. It is likely that the endogenous promoter can recruit a wider
Figure 3. ATF4 regulates cloned APOE promoter activity. (A) The pcDNA3.1-ATF4 or pcDNA3.1 control vector was transfected into U-87 cells
together with APOE promoter luciferase reporters and internal control plasmid Renilla, the APOE promoter activity was examined by dual-luciferase
assay. (B) APOE promoter reporter (with 2491A) or the deletion of the putative ATF4 binding sequence (2487 to 2469) of cloned APOE promoter
(21017 to +406 with 2491A) was transfected into U-87 cells, luciferase assay was then performed to determine the activity of the promoter. (C) A
series of 0.1 ug to 1.0 ug of ATF4 plasmids were transfected into WRL-68 cells together with APOE promoter reporters to determine the dose-
dependent effect of ATF4 on regulating APOE promoter activity. (D) ATF4 over-expression significantly down-regulated the activities of cloned APOE
promoters both with 2491A and 2491T allelic forms in U-87 and WRL-68 cell lines by dual-luciferase assay. The Y-axes represent the percent activity
of the APOE promoter relative to the control condition (set at 100%). All data were collected from three independent experiments in triplicate set up,
*p,0.05.
doi:10.1371/journal.pone.0024669.g003
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and thus renders such difference in response. Alternatively, the
endogenous APOE promoter may recruit repressors which bind
outside of the sequence of the cloned promoter to elicit a different
response.
The 2491A/T-dependent difference in APOE promoter activity
observed in this study and previous report cannot be explained by
ATF4 alone. It is speculated that other transcription factors are
involved in the 2491A/T-dependent transcription regulation of
APOE. Such speculation is supported by two lines of evidence.
First, the EMSA assays using mammalian cell nuclear extracts
showed two shift-bands, indicating more than one group of
nuclear proteins can bind to the APOE promoter 2491-spanning
sequence. Second, ATF4 is known to interact with several
transcription factors, i.e., C/EBP and p300 which have putative
binding sites within the studied APOE promoter 2491-spanning
sequence (predicted by TRANSFAC 6.0 database) [23,24,25]. It is
likely that C/EBP, p300 as well as other putative factors
interactive with ATF4 can elicit general and/or 2491A/T-
specific control to APOE transcription. Further investigation is
required to elucidate the identities and interactions of additional
transcription factors with the 2491-spanning region of APOE
promoter.
At molecular level, we have demonstrated the relationship
between the APOE 2491A/T genotype and the transcription
phenotype of the gene. At physiological level, the association
between the APOE promoter polymorphism and the risk of type 2
diabetes was tested for the 2491A/T, as well as for two additional
SNPs 2291G/T and +113G/C. The fact that the 2291 and +113
loci belong to a different LD block adjacent to the 2491 locus
opened the possibility for further exploring the APOE promoter
genotype-function relationship by haplotype analysis. No SNP or
haplotype association was detected between the APOE promoter
and the risk of type 2 diabetes. Since we previously reported an
association between APOM gene polymorphism and the disease
duration of type 2 diabetes [26], such association was also tested
for the three APOE promoter SNPs. Again, we did not detect an
Figure 4. ATF4 modulates endogenous APOE expression. (A)
WRL-68 cells were transfected with 100 pmol of ATF4 siRNA or control
siRNA. The expression levels of APOE and ATF4 were measured by Q-
PCR after normalizing to beta-actin. Q-PCR data of cells treated with
control siRNA were set as 1. (B) WRL-68 cells were transfected with 1 mg
of pcDNA3.1-ATF4 mammalian expression vector (or pcDNA3.1 empty
vector). Results are presented as the fold change of endogenous APOE
mRNA expression relative to that of the cells transfected with pcDNA3.1
vector controls (value set at 1). Data shown are from 3–4 independent
experiments in triplicate set-up, *p,0.05.
doi:10.1371/journal.pone.0024669.g004
Table 1. Associations between APOE polymorphisms and the risk of type 2 diabetes.
Genotype number (percentage) HWE Allele number (percentage)
2491A/T N AA AT TT N A T
Non-diabetic controls 589 546 (92.7%) 43 (7.3%) 0 (0) 0.358 1178 1135 (96.3%) 43 (3.7%)
Type 2 diabetes 586 544 (92.8%) 42 (7.2%) 0 (0) 0.368 1172 1130 (96.4%) 42 (3.6%)
P value 0.929 A: 0.933
OR (95% CI) 1.02 (0.67–1.59)
a 1.02 (0.66–1.57)
2219G/T N GG GT TT N G T
Non-diabetic controls 594 78 (13.1%) 288 (48.5%) 228 (38.4%) 0.384 1188 444 (37.4%) 744 (62.6%)
Type 2 diabetes 629 84 (13.4%) 291 (46.3%) 254 (40.1%) 0.964 1258 459 (36.5%) 799 (63.5%)
P value 263: 0.727 T+: 0.909
b G+: 0.475
c G: 0.649
OR (95% CI) 0.98 (0.70–1.37)
b 0.92 (0.73–1.16)
c 0.96 (0.82–1.14)
+113G/C N GG GC CC N G C
Non-diabetic controls 586 126 (21.5%) 291 (49.7%%) 169 (28.8%) 0.972 1172 543 (46.3%) 629 (53.7%)
Type 2 diabetes 624 126 (20.2%) 306 (49.0%) 192 (30.8%) 0.839 1248 558 (44.7%) 690 (55.3%)
P value 263: 0.722 C+: 0.575
d G+: 0.463
e G: 0.424
OR (95% CI) 1.08 (0.82–1.43)
d 0.91 (0.71–1.17)
e 0.94 (0.80–1.10)
HWE: p value for Hardy-Weinberg equilibrium; p values and ORs of genotypes were calculated by comparison between type 2 diabetes and non-diabetic control groups:
AA vs. AT
a,T + vs. GG
b, TT vs. G+
c,C + vs. GG
d, CC vs. G+
e.
doi:10.1371/journal.pone.0024669.t001
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type 2 diabetes (data not shown). However, it is important to note
that with the given effect and sample size, our study is
underpowered to reject the null hypothesis.
In conclusion, at molecular level, APOE gene transcription is
under the independent control of the promoter 2491A/T
polymorphism and the ER stress- responsive transcription factor,
ATF4. At physiological level, there is a lack of evidence of
association between the three APOE promoter SNPs 2491A/T
(rs449647), 2219G/T (rs405509), and +113G/C (rs440446) and
the risk of type 2 diabetes. These results encourage further
investigation of APOE promoter regulation under ER stress but
discourage the application of the three studied SNPs as risk
markers for type 2 diabetes.
Materials and Methods
Cell culture
293 (human kidney epithelial), WRL-68 (human hepatic
embryonic), and U-87 (human astrocytic) cell lines were obtained
from American Type Culture Collection (Manassas, VA, USA).
Cells were maintained in high glucose DMEM or RPMI 1640
(Gibco, Carlsbad, CA, USA) containing sodium bicarbonate, 10%
FBS, 100 unit/mL penicillin and 100 mg/mL streptomycin at
37uCi n5 %C O 2.
Yeast one-hybrid screening
Yeast one-hybrid system was adopted to screen for candidate
transcription factors interacting with the APOE promoter 2491A/
T-spanning sequence. Yeast strain Saccharomyces cerevisiae YM4271
and reporter vector pHISi-1 carrying the HIS3 reporter gene were
obtained from BD Bioscience (Palo Alto, CA, USA). The reporter
constructs pHISi-1-491A and pHISi-1-491T were generated with
three head-to-tail copies of the 21-bp bait sequence (59-CTG GTC
TCA AAC TCC TGA CCT-39)o r( 5 9-CTG GTC TCA ATC
TCC TGA CCT-39), which corresponds to the human APOE
promoter 2491A/T-spanning sequence (2501 to 2481).
Two independent sets of screenings for the GAL4 activating
domain AD tagged human brain MATCHMAKER cDNA library
(BD Bioscience) were performed with the constructed yeast
reporter strains, pHISi-1-491A and pHISi-1-491T, respectively.
Following the BD Clontech MATCHMAKER one-hybrid system
standard procedure, after three rounds of selections, 25 and 23
positive clones were recovered from pHISi-1-491A and pHISi-1-
491T baits screening respectively, with DNA sequencing per-
formed to confirm the identity of the recovered clones (service
provided by Macrogen, Seoul, Korea).
Plasmid constructs
Previously characterized APOE proximal promoter region
21017 to +406 containing the 2491A allelic form (GenBank
accession No.: AF055343) [19] was amplified by PCR using
commercial human genomic DNA as template (Promega,
Madison, WI, USA) and subcloned into firefly luciferase reporter
pGL3-basic vector (Promega). Site-directed mutagenesis was
performed using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) to introduce A to T substitution at
position 2491. APOE promoter 2491A/T-spanning sequence
deletion mutant D (2487 to 2469) was generated by PCR overlap
extension mutagenesis method.
ATF4 open reading frame (GenBank accession No.: BC073990)
was obtained by RT-PCR using 293 cells and subcloned into both
mammalian expression vector pcDNA3.1(+) (Invitrogen, Califor-
nia, USA) and E. coli expression vector pET507a, an in-house
modified vector from the pET3d vector (Novagen, Darmstadt,
Germany).
Cell transfection
For ATF4 overexpression, 1 mg of pcDNA3.1-ATF4 expression
vector or the control pcDNA3.1 vector was transiently transfected
into the cells using Lipofectamine2000 (Invitrogen) method
following manufacturer’s instructions. Cells were harvested for
RNA extraction 30 hrs post-transfection.
For ATF4 gene silencing, cells were transfected with 100 pmol
of ATF4 siRNA (59-gcc uag guc ucu uag aug att-39 and 59-uca ucu
aag aga ccu agg ctt-39) or an siRNA control which has a sequence
corresponding to ATF4 siRNA but mutated on five nucleotides
(59-gcg uag uuc gcu aag gug att-39 and 59-uca ccu uag cga acu acg
ctt-39) by Lipofectamine 2000 reagent (Invitrogen). Medium was
refreshed 4 h after transfection. The cells were harvested for RNA
extraction 2 days later.
RNA extraction and real-time PCR
Total RNA was extracted from the cells using Tri Reagent
(Molecular Research Center, Inc, Cincinnati, OH, USA). Reverse
transcription (RT) was performed using 5 mg of total RNA in a
total reaction volume of 20 ml by MMLV reverse transcriptase
system (GE Healthcare, Buckinghamshire, UK).
Real-time quantitative PCR was performed on the ABI Prism
7500 Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). The TaqMan probe and primer assays used were
Hs00171168_m1 (ABI) for ApoE and Hs00909569_g1 (ABI) for
ATF4, respectively. The relative mRNA levels were estimated by
the standard method using beta-actin as the reference gene.
Purification of recombinant ATF4 in E.coli
The pET507a-ATF4 expression plasmids were transformed into
E.coli BL21 (DE3, pLysS) strain (Novagen) in LB medium
containing the appropriate antibiotics (50 mg/ml of chloramphen-
icol and 100 mg/ml of ampicillin). The expression of His-tagged
ATF4 protein was induced by 0.2 mM of isopropyl-b-thiogalacto-
pyranose and harvested after 5 hrs culture at 37uC. The
HiTrap
TM Chelating HP column (GE Healthcare, Amersham,
UK) pre-charged with 0.1 M of NiSO4 was used for purification of
His-tagged ATF4 following the standard method [27].
Cell nuclear extract preparation
Cells nuclear extracts were prepared by NucBuster
TM Protein
Extraction kit (Novagen). The protein concentrations of nuclear
extracts were determined by DC protein assay kit (Bio-Rad,
Hercules, CA, USA) using BSA as a standard.
Electrophoretic mobility shift assay (EMSA)
The EMSA assays were performed with the use of mammalian
cell nuclear extracts or purified ATF4 and DIG-labeled oligonu-
cleotide probes according to the manufacturer’s instructions
(Roche, Penzberg, Germany). The 61-bp APOE promoter
2491A/T-spanning sequence were used as the double-stranded
probes: 2491A 59-GTT TCA CCA TGT TGG CCA GGC TGG
TCT CAA ACT CCT GAC CTT AAG TGA TTC GCC CAC
TGT G-39 and -491T 59-GTT TCA CCA TGT TGG CCA
GGC TGG TCT CAA TCT CCT GAC CTT AAG TGA TTC
GCC CAC TGT G-39. For the supershift assays, anti-ATF4
antibody (Santa Cruz, CA, USA) was used.
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A total of 5610
7 cells were used for each ChIP assay and
immunoprecipitated with 1 mg of ATF4 antibody following the
standard protocol [28]. The immunoprecipitated genomic DNA
was then subjected to PCR using the following primers adjacent to
the APOE promoter 2491A/T-spanning sequences: forward
primer 59-TTC AAG CGA TTC TCC TGC CT-39; reverse
primer 59-TGG GGA TCT GGA CTC CTG GA-39.
Dual-luciferase reporter assay
APOE promoter firefly luciferase reporter constructs were
transfected into cells by Lipofectamine
TM 2000 reagent (Invitro-
gen) together with Renilla luciferase reporter pRL-CMV vector
(Promega) which provided the internal control for transfection. To
evaluate the effect of ATF4 on APOE promoter activity, APOE
promoter firefly luciferase reporter constructs and pcDNA3.1-
ATF4 expression construct (or pcDNA3.1 empty vector), together
with the Renilla luciferase reporter vector were co-transfected into
cells by Lipofectamine
TM 2000 reagent. Cells were harvested
30 hrs post-transfection and luciferase activities were analyzed by
the dual-luciferase assay kit (Promega). The luminometric
measurements were performed with a Lumat LB9501 luminom-
eter (Berthold Technologies, Wildbad, Germany).
Case selection
All subjects were of southern Han Chinese ancestry residing in
Hong Kong. The population consisted of 630 unrelated early-
onset (diagnosed at #40 years) type 2 diabetic patients selected
from Hong Kong Diabetes Registry [29] and 595 non-diabetic
control subjects [fasting plasma glucose (FPG),6.1 mmol/l]
recruited from the general population participating in a commu-
nity-based cardiovascular risk screening program as well as
hospital staff. The use of the early-onset patients aimed at
enriching the genetic background. The clinical characteristics of
the study population are summarized in Table S1. This study was
approved by the Clinical Research Ethics Committee of the
Chinese University of Hong Kong. An informed consent was
obtained for each participant. All subjects underwent detailed
clinical investigation as described previously [29,30]. For each
participant, a fasting blood sample was collected for the
measurement of plasma glucose, lipid profile and for extraction
of genomic DNA.
Genotyping of APOE promoter polymorphisms
DNA samples were extracted from whole blood using the
phenol-chloroform method. APOE proximal promoter 2491A/T
(rs449647), 2219G/T (rs405509) and +113G/C (rs440446)
genotypes were determined by Sequenom analysis (service
provided by McGill University and Genome Quebec Innovation
Centre, Montreal, Canada).
Statistics
In the case-control study, APOE promoter SNPs genotypes
(grouped into 263 table) were compared by chi-square test.
Hardy-Weinberg equilibrium (HWE) was assessed by chi-square
test in each study group separately. Odds ratios (OR) with 95%
confidence interval were calculated by Epi6 software (World
Health Organization, Geneva, Switzerland). Intragenic linkage
disequilibrium (LD) in pairs of SNPs and haplotype imputation
were analyzed by Haploview (Broad Institute of MIT and
Harvard, USA, version 4.2). For the dual-luciferase reporter
assays, results were analyzed by Student’s t-test or ANOVA with
statistical significance threshold set at p,0.05. Statistical analyses
were performed using the SPSS program (SPSS version 12.0,
Chicago, IL, USA).
Supporting Information
Table S1 P value: calculated by comparing Non-diabetic control
vs. Type 2 diabetes groups.
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Table S2 D9.80 indicates the existence of linkage disequilib-
rium between the two markers. r
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mapping in association studies. When D9.80 and r
2 is close to 1,
the two markers are in LD and most probably display similar
disease association profile.
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